ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
US$0.010
arrow_upward
+9,900.00%(+0.0099) 1D
4월 30일, 오후 4시 0분 0초 GMT-4 · USD
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoADAPY의 주요 통계 생성 중...
시가
US$0.00
고가
US$0.01
저가
US$0.00
시가총액
135.18만
평균 거래량
28.15만
거래량
43.11만
52주 최고가
US$0.36
52주 최저가
US$0.00
EPS
-US$0.66
베타
2.42
유통 주식수
2.65억
직원 수
506
뉴스 기사
웹 소스 기반
프로필
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Adaptimmune Therapeutics PLC - ADR에 관한 정보